Anti-Obesity Treatments Report - Analysis & Forecasts 2009-2024

Obesity has been described as a ‘public health time-bomb'. In 2005, the World Health Organization estimated that approximately 400 million individuals are obese. Prevalence of obesity is rising worryingly in many countries, despite campaigns emphasising the link between being overweight and contracting diabetes. This new report - Anti-Obesity Treatments 2009-2024 - explains those trends in commercial terms. In two of the largest national markets for anti-obesity treatments - the US and UK - over 20% of the population are seriously overweight. Obesity is a major risk factor in a number of other serious disorders, particularly diabetes and heart disease. Importantly, the financial burden of obesity and its associated conditions - both direct and indirect costs - are vast. Obesity is a serious, chronic condition with an emerging market for therapeutic products, as we show in this study. High socioeconomic costs and increasing prevalence are inspiring government initiatives to deal with the problem, with obesity becoming one of the most prominent global health concerns worldwide. Visiongain recognizes the contribution of drugs in this important emerging market, as diet and exercise are frequently not successful alone. We predict that new classes of drugs will invigorate the market - driving total sales in the next decade. In this report you will find out about those treatments, especially their sales potential.

Drug sales in the global anti-obesity market approached $2bn in 2008, with the market to grow substantially over the forecast period 2009-2024. This growth will be associated with a complex environment of label changes, reformulations, patent expiry, OTC switching and new product launches. Those opportunities are highlighted by the extensive R&D pipeline, crowded with novel therapies to improve treatment of obesity. Which new treatments have blockbuster potential? Our report will cover this and other important matters. Importantly, too, prevalence of obesity is rising in Latin America, India and China in particular - important pharmaceutical markets covered here.

Anti-Obesity Treatments 2009-2024 provides detailed analysis of the global anti-obesity market, with comprehensive sales forecasting. With a rigorous study of sources, including commercial databases, company reports, industry news and first-hand interviews with experts in the obesity sector, this report is a unique opportunity to discover how your company can develop over the next 5 years. The result is a comprehensive market- and industry-based report with detailed analyses and informed opinion that you will not find anywhere else.

Anti-Obesity Treatments 2009-2024 highlights the following essential aspects of the market:

A global forecast for the anti-obesity drugs market with comprehensive discussions
Sales forecasts for the current-leading drugs
Assessment of new drug releases, both therapeutically and commercially
Sales forecasts for the leading national anti-obesity markets, as well as for emerging national markets
Discussion of strengths, weakness, opportunities and threats (SWOT) facing major stakeholders in the anti-obesity drug sector
Extensive analysis of pipeline developments, including avenues for future research
Discussion of current un-met and under-met needs in the anti-obesity market, revealing both therapeutic needs and commercial opportunities.

Why you should buy this report:

To receive a comprehensive analysis of the prospects for anti-obesity therapies from 2009-2024, including predicted revenues, growth rates and other key metrics
To identify key pipeline developments, the most promising therapy classes and potential methods of treatment
To discover the important drivers and restraints for the global anti-obesity market, including factors affecting leading national markets
To find out where the global anti-obesity market is heading - both technologically and commercially - from the present onwards.

This report is essential reading for anyone in the pharmaceutical and healthcare sector with an interest in obesity and related conditions. Purchasing this report will help you to recognise those important market opportunities and understand the possibilities there. You can order today. I look forward to receiving your order.

Table of Contents

1 Executive Summary: Anti-Obesity Treatments 2009-2024

2 An Introduction to Obesity and Its Treatment

2.1 What is Obesity?

2.1.1 Fat is a Necessary Component of the Body

2.1.2 Obesity is a Chronic Disease

2.1.3 Body Weight is Dependent upon Several Factors

2.2 How is Obesity Measured?

2.2.1 Weight-for-Height Tables

2.2.2 Waist Circumference

2.2.3 Body Mass Index (BMI)

2.3 How Serious is the Problem?

2.3.1 Prevalence

2.3.2 Risk Factors of Other Diseases (Co-Morbidities)

2.3.3 Economic Costs

2.4 Historical Causes and Lifestyle Changes

2.4.1 Urbanisation, Modernisation and Economic Development

2.4.2 Developed Countries and in Developing Nations

2.5 Factors Causing Obesity

2.5.1 Lifestyle, Environment and Diet

2.5.2 Behaviour

2.5.3 Psychological Factors

2.5.4 Genetics

2.5.5 Antecedent Illnesses and Treatments

2.5.6 Other Causes

2.6 Treatment of Obesity

2.6.1 Lifestyle and Behavioural Changes

2.6.2 Unapproved Drugs

2.6.3 Alternative Therapies

2.6.4 Pharmacotherapy

2.6.5 Surgical Options

2.6.6 Drugs have a Role in the Treatment of Obesity.

2.7 Pharmacotherapy in the Treatment of Obesity

2.7.1 Lipase Inhibitors

2.7.2 Anorectic Drugs

2.7.3 Off-Label Use of Drugs

2.8 Need for Future Development in the Treatment of Obesity

2.8.1 Unmet Needs and Market Potential

3 The World Market for Anti-Obesity Drugs, 2009-2024

3.1 The Current Anti-Obesity Market Climate - a Potential Blockbuster Market

3.2 Leading Companies in the Anti-Obesity Market

3.3 Market History and the Current Situation

3.3.1 The Effect of Pondimin, Redux and Public Opinion on the Anti-Obesity Market

3.3.2 Rimonabant and other Cannabinoid Receptor Antagonists

3.3.3 Phentermine

3.4 Total Anti-Obesity Market Forecast 2009-2024

3.4.1 Market Growth in 2009-2024

3.4.2 Drugs after 2012

3.5 Xenical Forecast 2009-2024

3.5.1 Will Generic Erosion Drive Down Xenical's Sales?

3.5.2 Competition Increases with New Releases

3.5.3 Will Xenical be Driven Out by Newer Rivals?

3.6 Reductil/Meridia Forecast 2009-2024

3.6.1 How Will Competition Affect Sales?

3.6.2 Expiry of Patents in 2013

3.7 Alli Forecast 2009-2024

3.7.1 Early Launch-Stocking

3.7.2 European Launch

3.7.3 Is Alli Failing to Distinguish Itself?

3.8 Dinintel Forecast 2009-2024

3.8.1 Will the Rapidly Evolving Anti-Obesity Market Will Leave Dinintel Behind?

3.9 Total Other Drugs Forecast 2009-2024

3.9.1 Generic Competitors

3.9.2 New Drug: Contrave (Orexigen)

3.9.3 New Drug: Lorcaserin (Arena)

3.9.4 New Drug: Qnexa (Vivus)

3.9.5 New Drug: Liraglutide (Novo Nordisk)

3.9.6 New Drug: Empatic/Excalia (Orexigen)

3.10 Market Summary

3.10.1 New Drugs and the Market

3.10.2 Lack of Innovation and the Market Opportunities?

3.10.3 The Problems with Anorectic Drugs

3.10.4 The Problems with Lipase Inhibitors

3.10.5 The Future of Anti-Obesity Treatments

4 Anti-Obesity Treatments - SWOT Analysis

4.1 Strengths

4.1.1 Long-Term Therapy with Anti-Obesity Drugs

4.1.2 Prospects of Multiple Indications for Anti-Obesity Drugs

4.1.3 Off-Label Potential and Competition

4.1.4 The Anti-Obesity Market is Ready to be Revolutionised

4.1.5 Failure of Rimonabant Leaves Vacuum in the Market

4.1.6 New Drugs May Not Fill the Entirety of Customer Needs

4.2 Weaknesses

4.2.1 Limited Efficacy

4.2.2 Undesirable Side-Effects Limit Market Potential of Anti-Obesity Medications

4.2.3 Increased Competition by both Impending New Releases and Generic Competitors

4.2.4 Regulatory Hurdles have Become Stricter - Companies Pay the Price

4.2.5 Pharmacotherapy Will Never be the First Line of Treatment?

4.3 Opportunities

4.3.1 Rising Prevalence Drives Market Potential

4.3.2 Unmet Market Needs - Can Drugs Solve this Problem?

4.3.3 A Safe and Effective Anti-Obesity Treatment has Applications in Both the Clinical and Cosmetic Sectors

4.3.4 How the Changing Government Agenda and the High Economic Costs of Obesity Will Drive Growth in the Anti-Obesity Market

4.3.5 Diet and Exercise May be the Mainstay Treatment, but this Approach is not Always Effective

4.4 Threats

4.4.1 Reimbursement May Continue to be a Limiting Factor

4.4.2 Long-Term Safety Issues Continue to Stunt Growth

4.4.3 Opinion of Both the Public and Prescribing Bodies is Heavily Dependent upon Individual Drug Successes and Success of the Market as a Whole

4.4.4 Will Healthier Lifestyles Limit the Current Need for Anti-Obesity Drugs?

5 Pipeline Developments in Anti-Obesity Treatments

5.1 Treatments in Phase III

5.1.1 Lorcaserin

5.1.2 Qnexa

5.1.3 Contrave

5.1.4 Cetilistat

5.2 Treatments in Phase II

5.2.1 Empatic/Excalia

5.2.2 Liraglutide

5.2.3 Obinepitide

5.2.4 Solabegron

5.2.5 Tesofensine

5.2.6 Velneperit

5.2.7 Histalean

5.2.8 Sodium Tungstate

5.2.9 Serglifozin Etabonate

5.2.10 Pramlintide & Metreleptin

5.2.11 Hoodia gordonii Extract

5.2.12 MTP Inhibitor

5.2.13 TM 30339

5.2.14 SLx 4090

5.2.15 MK 0493

5.2.16 KRP 204

5.2.17 FM VP4

5.2.18 AZD 2207

5.2.19 CE 326597

5.3 Treatments in Phase I

5.3.1 Trodusquemine

5.3.2 THCV

5.3.3 Oral PYY3-36

5.3.4 ATHX 105

5.3.5 AZD 1175

5.3.6 AZD 1656

5.3.7 BVT 74316

5.3.8 CP 404

5.3.9 KD 3010

5.3.10 PRX 07034

5.3.11 PSN 602

5.3.12 TKS 1225

5.3.13 V 24343

5.3.14 TTP 435

5.4 Other Promising Pipeline Developments

5.4.1 Melanotan

5.4.2 Increasing Mitochondrial Activity to Increase Energy Expenditure

5.4.3 Inhibiting the Creation of Fat Stores after Gut Absorption

7 Experts' Views on the Main Issues in the Treatment of Obesity

7.1 An Interview with Dr. Tyrberg from The Burnham Institute Diabetes and Obesity Research Centre

7.1.1 The Effect of Anti-Obesity Drugs on the Obese Population

7.1.2 The Cause-Effect Relationship between Diet, Obesity and Type 2 Diabetes

7.1.3 Off-Label Indications and Diabetes Treatments Used to Treat Obesity

7.1.4 Obesity as a Lifestyle Disease?

7.1.5 The Future of Anti-Obesity Treatments and the Role Diet and Exercise Will Play

7.1.6 The Role of Pharmaceutical Companies, Ethics and the Cosmetic Use of Anti-Obesity Treatments

7.1.7 Unmet Medical Needs in the Treatment of Obesity

7.1.8 The Future of the Anti-Obesity Market

7.2 Commentaries and Views from Other Experts in the Field

7.2.1 The Most Important Unmet Medical Needs in the Treatment of Obesity

7.2.2 The Future of Anti-Obesity Treatment

7.2.3 Funding of Anti-Obesity Treatments

7.2.4 The Anti-Obesity Market in Developing Nations

7.2.5 Concluding Thoughts

8 Conclusions

8.1 Obesity is a Chronic Disease with Serious Health Implications

8.2 The Prevalence and Economic Costs of Obesity

8.3 The Modern Lifestyle has Contributed Significantly to Obesity

8.4 Obesity is Caused by a Complex Interplay of Factors

8.5 Obesity Treatments and the Role of Pharmaceuticals

8.6 The Unmet Needs and Market Potential for Anti-Obesity Treatments

8.7 The Anti-Obesity Market Will Expand from 2009-2024

8.8 The Main Drivers and Restraints of the Anti-Obesity Market

Some Organisations Mentioned in this Report

7TM Pharma

Abbott

Ache Laboratories

Actavis

Alizyme

American Home Products

Amylin

Arena

AstraZeneca

Athersys

Barcelona University

Bayer

Biovitrum

Bristol-Myers Squibb

Clinuvel

Compellis

Council for Scientific and Industrial Research

Duke University

Eli Lilly

EMEA

Emisphere

EMS

Epix

FDA

Forbes Medi-Tech

Gate Pharmaceuticals

Genaera

GlaxoSmithKline

Graceway Pharma

GW Pharmaceuticals

Han Wha

Hanmi

Inova Pharma

Johnson & Johnson

Kalypsys

Kissei

Kyorin

Louisiana State University

Medley

Merck & Co.

NeuroSearch

Novartis

Novo Nordisk

Nycomed Pharma

OBEcure

Orexigen

OSI Pharmaceuticals

Pfizer

Phytopharm

Roche

Sanofi-Aventis

Shionogi

Sirtris Pharmaceuticals

Solvay

Surface Logix

Takeda

Teva

The Burnham Institute

Transition

TransTech

URL Pharma

Vernalis

Vivus

Wyeth Pharmaceuticals